In Brief: Cardiac Pathways Corp.
This article was originally published in The Gray Sheet
Executive Summary
Cardiac Pathways Corp.: Receives investigational device exemption from FDA for its Arrhythmia Mapping System, a cardiac ablation system that utilizes a 64-electrode mapping "basket" catheter to "diagnose and treat patients with complex tachyarrhythmias." The Sunnyvale, California-based company says it will begin a multicentered feasibility study of the system within two weeks at Brigham & Women's Hospital in Boston and St. Mary's Hospital in Rochester, Minnesota. The study will make privately held Cardiac Pathways "the first company to begin clinical trials of an integrated mapping system in the left ventricle," according to the firm...